PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.41%
Negative revenue growth while Healthcare median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-12.41%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-27.47%
Negative EBIT growth while Healthcare median is -0.48%. Seth Klarman would check if external or internal factors caused the decline.
-27.47%
Negative operating income growth while Healthcare median is -2.06%. Seth Klarman would check if structural or cyclical issues are at play.
-27.92%
Negative net income growth while Healthcare median is -1.33%. Seth Klarman would investigate factors dragging net income down.
-20.00%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-20.00%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
6.47%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.47%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-21.90%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-21.77%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2645.13%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
92.60%
OCF/share CAGR of 92.60% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
85.56%
3Y OCF/share growth of 85.56% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-3055.33%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
92.82%
5Y net income/share CAGR > 1.5x Healthcare median of 1.61%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
82.14%
3Y net income/share CAGR of 82.14% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
1796.75%
Equity/share CAGR of 1796.75% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-58.41%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
18.52%
3Y equity/share CAGR of 18.52% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Asset growth of 0.03% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-6.32%
Negative BV/share change while Healthcare median is -0.06%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-20.42%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
29.66%
R&D growth of 29.66% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
16.61%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.